Source: Withings
Withings launched the Body Scan 2, a "longevity station" designed to bring clinical-grade health monitoring into the home. Debuting at CES 2026, the device introduces over 60 biomarkers, including what the company claims are first-of-their-kind home features such as hypertension risk notifications and assessments of cardiac pumping efficiency via Impedance Cardiography.
The station surpasses traditional weight tracking by utilizing ultra-high-frequency bioimpedance spectroscopy to assess cellular health, metabolic efficiency, and glycemic regulation. By capturing these metrics through a 90-second full-body scan involving the hands, feet, and posture, Body Scan 2 aims to detect physiological imbalances years before symptoms of chronic illness appear.
Body Scan 2 is scheduled for release in some markets in the second quarter. It will be priced at US$599.95 (approximately CA$831) and will be available through major retailers, including Amazon and Withings' official website.